GSK To Pay States, DC $41M Over Drugmaking Lapses

Law360, New York (June 23, 2011, 5:06 PM EDT) -- GlaxoSmithKline LLC and a related company will pay $40.75 million to the District of Columbia and 37 states, including Oregon and Illinois, to resolve allegations of substandard manufacturing processes at one facility that resulted in adulterated drugs, the parties announced Thursday.

The agreement follows a $750 million settlement that GSK reached in October to resolve criminal and civil complaints over events at the now shuttered Puerto Rico factory, where the company manufactured the popular antidepressant Paxil, diabetes medication Avandamet and other drugs.

The District of Columbia...
To view the full article, register now.